Polpharma Biologics S.A.

Polpharma Biologics, founded in 2013 as a Polpharma spin-off, is one of Europe's most modern biotech companies. Pipeline of 7 biosimilars including FYB201 (ranibizumab, with Bioeq) and Tyruko® (natalizumab, with Sandoz, FDA-approved in 2025 for MS and Crohn's). Facilities in Gdańsk, Duchnice (Poland) and Utrecht (Netherlands) are EMA and FDA certified. Following demerger, CDMO services operate as Rezon Bio, and biosimilars from Switzerland.